Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

Biotechs face upward battle with recruiting patients on obesity trials

Following plans to add cohorts in an ongoing Phase II weight-loss study, Aphaia Pharma’s CSO Steffen-Sebastian Bolz says there are now rising challenges with the recruitment of patients in obesity trials.

Drug Discovery World

Selective Translation Regulator Inhibitors: Depriving cancer of what it needs

In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.

opthalmology times

Claris Bio’s journey toward treating neurotrophic keratitis

So with positive data, and in the summer, we would begin another pivotal trial. This trial will be slightly different in that it will be slightly larger and will include both the US and European sites.


Obesity drugmaker lands first biopharma uplisting onto Nasdaq since last summer

But behind the industry’s first uplisting of 2024, from San Diego biotech Skye Bioscience, is investors’ interest in an area of drug R&D that every therapeutics developer wants in on right now: the next wave of obesity medications.


How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics

Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body’s immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.


AACR 2024: What Cancer Researchers Are Talking About

Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.


ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint

Arrowhead Pharmaceuticals unveiled Phase IIb data for its investigational RNAi therapy plozasiran at ACC24, demonstrating steep triglyceride reductions at 24 weeks in patients with severely elevated triglyceride levels who are at risk of developing acute pancreatitis.

NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

Aki Ko, chief executive officer at Elixirgen Therapeutics, sat down with NeurologyLive® at the conference to discuss the promise behind the therapy and why it can be successful in treating DMD.